公开(公告)号：US20210268036A1

公开(公告)日：2021-09-02

申请号：US17168944

申请日：2021-02-05

Applicant: The Regents of the University of California

Inventor： Elaine Y. Hsiao ,  Thomas Fung

IPC: A61K35/742 ,  A61K45/06 ,  A61K9/00

Abstract: Provided herein are methods and compositions related to promoting or reducing colonization of spore-forming bacteria in a patient's gut, comprising administering a serotonin receptor agonist or a selective serotonin reuptake inhibitor, respectively. In some aspects, provided herein are methods of modulating lipid and steroid metabolism.

公开(公告)号：US11883441B2

公开(公告)日：2024-01-30

申请号：US17486299

申请日：2021-09-27

Applicant: The Regents of the University of California

Inventor： Elaine Y. Hsiao ,  Jessica Yano ,  Helen E. Vuong ,  Christine Olson

IPC: A61K35/741 ,  A61K39/02 ,  A61K35/00 ,  A61K35/74 ,  A61K9/00 ,  A23L33/135 ,  A23L33/00 ,  A61P25/00

CPC classification number: A61K35/74 ,  A23L33/135 ,  A23L33/30 ,  A61K35/741 ,  A61K39/0216 ,  A61P25/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K2035/115

Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

公开(公告)号：US20220184144A1

公开(公告)日：2022-06-16

申请号：US17486299

申请日：2021-09-27

Applicant: The Regents of the University of California

Inventor： Elaine Y. Hsiao ,  Jessica Yano ,  Helen E. Vuong ,  Christine Olson

IPC: A61K35/74 ,  A23L33/00 ,  A23L33/135 ,  A61P25/00 ,  A61K39/02

Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

公开(公告)号：US20220096575A1

公开(公告)日：2022-03-31

申请号：US17443273

申请日：2021-07-23

Applicant: California Institute of Technology ,  The Regents of the University of California

Inventor： Brittany D. Needham ,  Sarkis K. Mazmanian ,  Gil Sharon ,  Masanori Funabashi ,  Michael A. Fischbach ,  Elaine Y. Hsiao ,  Paul H. Patterson

IPC: A61K35/747 ,  A23L33/135 ,  A61P25/22 ,  A61K9/00

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

公开(公告)号：US11744867B2

公开(公告)日：2023-09-05

申请号：US17443273

申请日：2021-07-23

Applicant: California Institute of Technology ,  The Regents of the University of California

Inventor： Brittany D. Needham ,  Sarkis K. Mazmanian ,  Gil Sharon ,  Masanori Funabashi ,  Michael A. Fischbach ,  Elaine Y. Hsiao ,  Paul H. Patterson

IPC: A61K35/741 ,  A61K35/747 ,  A23L33/135 ,  A61P25/22 ,  A61K9/00

CPC classification number: A61K35/747 ,  A23L33/135 ,  A61K9/0031 ,  A61K9/0053 ,  A61P25/22

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

公开(公告)号：US20220233611A1

公开(公告)日：2022-07-28

申请号：US17609269

申请日：2019-10-31

Applicant: The Regents of the University of California

Inventor： Elaine Y. Hsiao ,  Helen E. Vuong

IPC: A61K35/742 ,  A61K31/04 ,  A61K31/197 ,  A61K31/4166 ,  A61K31/198 ,  A61K35/741 ,  A61P25/28

Abstract: Disclosed herein are methods for promoting healthy neural development in an unborn baby, which include administering to a maternal subject gestating the unborn baby a composition or a bacterial composition. Compositions can include trimethylamine N-oxide (TMAO), 5-aminovalerate (5-AV), imidazole propionate (IP), hippurate (HIP), or a combination thereof, and the bacterial compositions can include bacteria of the order Clostridiales. Also disclosed are methods for conditioning a female subject for bringing about offspring with healthy neural development. Additionally disclosed are methods for reducing adverse effects of antibiotic treatment on an unborn baby in a pregnant subject. Also disclosed are methods for selecting a female subject for conditioning to foster healthy neural development in offspring.

公开(公告)号：US20220218762A1

公开(公告)日：2022-07-14

申请号：US17615297

申请日：2020-06-01

Applicant: The Regents of The University of California

Inventor： Elaine Y. Hsiao ,  Christine Olson ,  Alonso Iniguez

IPC: A61K35/74 ,  A61P25/28 ,  C07K16/24

Abstract: The present disclosure provides methods of treating hypoxia-induced cognitive impairment. Also disclosed are microbiome modulators, such as ketogenic-diet-suppressed bacterial species or antibiotics effective against a ketogenic-diet-boosted bacterial species, for use in treatment of cognitive impairment. The disclosure also provides methods of selecting a subject having hypoxia-induced cognitive impairment and methods of obtaining a prognostic indicator of hypoxia-induced cognitive impairment in a subject who receives a dosage of a microbiome modulator.

公开(公告)号：US11224624B2

公开(公告)日：2022-01-18

申请号：US16485403

申请日：2018-02-13

Applicant: California Institute of Technology ,  The Regents of the University of California

Inventor： Brittany D. Needham ,  Sarkis K. Mazmanian ,  Gil Sharon ,  Masanori Funabashi ,  Michael A. Fischbach ,  Elaine Y. Hsiao ,  Paul H. Patterson

IPC: A61K35/741 ,  A61K35/747 ,  A23L33/135 ,  A61P25/22 ,  A61K9/00

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.